| 000 | 01831 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518100938.0 | ||
| 264 | 0 | _c20210226 | |
| 008 | 202102s 0 0 eng d | ||
| 022 | _a1873-3476 | ||
| 024 | 7 |
_a10.1016/j.ijpharm.2020.119375 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiang, Pan | |
| 245 | 0 | 0 |
_aPreparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma. _h[electronic resource] |
| 260 |
_bInternational journal of pharmaceutics _cJun 2020 |
||
| 300 |
_a119375 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xchemistry |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Compounding |
| 650 | 0 | 4 | _aDrug Liberation |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHep G2 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aNanoparticles |
| 650 | 0 | 4 |
_aSesquiterpenes _xchemistry |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 |
_aSorafenib _xchemistry |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aWu, Hangyi | |
| 700 | 1 | _aZhang, Zhenhai | |
| 700 | 1 | _aJiang, Shulong | |
| 700 | 1 | _aLv, Huixia | |
| 773 | 0 |
_tInternational journal of pharmaceutics _gvol. 583 _gp. 119375 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ijpharm.2020.119375 _zAvailable from publisher's website |
| 999 |
_c30909952 _d30909952 |
||